Trial Profile

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (FASCINATE-N)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adebrelimab (Primary) ; BAT 8003 (Primary) ; Camrelizumab (Primary) ; Carboplatin (Primary) ; Cyclophosphamide (Primary) ; Dalpiciclib (Primary) ; Epirubicin (Primary) ; Fuzuloparib (Primary) ; Goserelin (Primary) ; Letrozole (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Pyrotinib (Primary) ; Trastuzumab (Primary) ; Trastuzumab rezetecan (Primary)
Indications Advanced breast cancer; Breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms FASCINATE-N

28 May 2026 Planned End Date changed from 1 Sep 2028 to 1 Sep 2029.
28 May 2026 Planned primary completion date changed from 31 Dec 2026 to 31 Dec 2027.
22 Aug 2025 Planned End Date changed from 1 Sep 2025 to 1 Sep 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com